Share on StockTwits

Acura Pharmaceuticals (NASDAQ:ACUR) Director William G. Skelly unloaded 5,000 shares of the company’s stock on the open market in a transaction that occurred on Tuesday, May 20th. The shares were sold at an average price of $1.21, for a total value of $6,050.00. Following the completion of the transaction, the director now directly owns 9,600 shares in the company, valued at approximately $11,616. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Several analysts have recently commented on the stock. Analysts at MLV & Co
cut their price target on shares of Acura Pharmaceuticals from $2.25 to $2.00 in a research note on Friday, May 9th.

Acura Pharmaceuticals (NASDAQ:ACUR) traded down 0.83% on Wednesday, hitting $1.20. The stock had a trading volume of 22,390 shares. Acura Pharmaceuticals has a 52 week low of $1.08 and a 52 week high of $2.59. The stock has a 50-day moving average of $1.31 and a 200-day moving average of $1.60. The company’s market cap is $58.6 million.

Acura Pharmaceuticals (NASDAQ:ACUR) last issued its quarterly earnings data on Monday, May 5th. The company reported ($0.08) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.05) by $0.03. On average, analysts predict that Acura Pharmaceuticals will post $-0.31 earnings per share for the current fiscal year.

Acura Pharmaceuticals, Inc, is a specialty pharmaceutical company engaged in the research, development and commercialization of products focused on addressing medication abuse and misuse, utilizing its Aversion and Impede Technologies.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.